Catalyst Biosciences, Inc. (NASDAQ:CBIO) went up to recover about 192.93% since recording its record low price of $3.11. The stock experienced -63.92% slump, arriving at $9.11 on 06/18/2018. During the day, the stock price traveled from $8.91 to $12. This company shares are 493.41% off its target price of $54.06 and the current market capitalization stands at $111.42M. The recent change has given its price a -64.76% deficit over SMA 50 and -75.38% deficit over its 52-week high. The stock witnessed -67.46% declines, -67.99% declines and -8.26% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CBIO’s volatility during a week at 11.39% and during a month it has been found around 8.01%.Catalyst Biosciences, Inc. (CBIO) Top Holders
Institutional investors currently hold around $231 million or 80.2% in CBIO stock. Look at its top three institutional owners. Acuta Capital Partners, Llc owns $29.16 million in Catalyst Biosciences, Inc., which represents roughly 26.17% of the company’s market cap and approximately 12.62% of the institutional ownership. Similar statistics are true for the second largest owner, Sio Capital Management, Llc, which owns 1,149,989 shares of the stock are valued at $29.04 million. The third largest holder is Venbio Select Advisor Llc, which currently holds $25.86 million worth of this stock and that ownership represents nearly 23.21% of its market capitalization.
At the end of 03/31/2018 reporting period, 46 institutional holders increased their position in Catalyst Biosciences, Inc. (NASDAQ:CBIO) by some 6,442,570 shares, 9 decreased positions by 187,535 and 8 held positions by 2,527,072. That puts total institutional holdings at 9,157,177 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 2,961,900 shares while 7 institutional investors sold out their entire positions totaling 143,590 shares.Catalyst Biosciences, Inc. (NASDAQ:CBIO) Insider Trades
Multiple company employees have indulged in significant insider trading. Catalyst Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Flynn James E has sold 71,778 shares of Catalyst Biosciences, Inc. (CBIO) in trading session dated Mar. 08, 2018. These shares are worth $2,191,382 and were traded at $30.53 each. The SEC filing shows that Flynn James E performed a sale of 71,778 shares. The disposed these shares by way of transaction on Mar. 08, 2018. The company’s shares were given away at $30.53 per share worth to an income of some $2,191,382 on account of Flynn James E.
President & CEO, Usman Nassim, purchased 267 common shares of Catalyst Biosciences, Inc. (CBIO) in the open market. In a transaction dated Dec. 17, 2015, the shares were bought at an average price of $30, giving away a sum of $8,010. After this purchase, 9,282 common shares of CBIO are directly owned by the insider, with total stake valued at $84,559.
In the transaction dated Dec. 17, 2015, the great number of shares acquired came courtesy the CFO; Payne Fletcher added a total of 667 shares at an average price of $30, amounting to approximately $20,010. The insider now directly owns 1,669 shares worth $15,205.
Several analysts have released their opinion on Catalyst Biosciences, Inc. (NASDAQ:CBIO), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.